Alliance A191901
Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions
Patients are asked to take part in this research study because their doctor has prescribed taking an endocrine therapy (ET) medication daily by mouth as part of their treatment for hormone receptor positive breast cancer. ET medication is also called hormone therapy and it is used to slow or stop the growth of hormone receptor positive breast cancer cells.
We are doing this study because we want to find out if using either text message reminders or telephone-based counseling, or both is better or worse than the usual approach for making sure that women take their ET medication as prescribed. This is also called medication adherence.
Medication adherence is how well patients take the medication as prescribed by their doctors and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients.
The usual approach is defined as the medical care most people get while taking ET medication, including regular follow-up appointments and advice from their medical care providers while taking the medication.
Click Here for more information
Principle Investigator: Priya Gor, M.D.
IRB-2021-04
Pilot Study to evaluate the Impact of a Home-Based Exercise Program on Cancer-Related Fatigue in Breast Cancer Patients Undergoing Curative-Intent Chemotherapy
Patients are being asked to take part in this study because they have breast cancer and are undergoing curative-intent chemotherapy.
This study will examine the feasibility of home-based exercises in reducing cancer-related fatigue in breast cancer patients who are receiving curative-intent chemotherapy treatment. The results of participants who are evaluated by a physical therapist and provided with exercises to do at home will be compared with a group of participants who have not be instructed about an exercise program to do at home.
The purpose of the study is to determine the feasibility of a specific home-based exercise program in reducing cancer-related fatigue in breast cancer patients undergoing curative-intent chemotherapy. The results of this study will be measured by responses to a survey designed to assess feelings of fatigue and other symptoms.
Principle Investigator: Priya Gor, M.D.
NRG-BR009
NRG-BR009, A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score = 25 (OFSET)
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among premenopausal, early- stage breast cancer (EBC) patients with estrogen receptor (ER)-positive, HER2-negative tumors and 21-gene recurrence score (RS) between 16-25 (for pN0 patients) and 0-25 (for pN1 patients).
Click Here for more information
Principle Investigator: Priya Gor, MD
SWOG S2212
Protocol S2212, Shorter Anthracycline-Free Chemo Immunotherapy Adapted to Pathological Response in Early Triple Negative Breast Cancer (SCARLET), A Randomized Phase III Study
The purpose of this study is to compare the usual chemo-immunotherapy treatment for triple negative breast cancer to a shorter chemo-immunotherapy treatment that uses fewer drugs.
This study will help the study doctors find out if the shorter treatment without anthracycline chemotherapy works the same, as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer. To decide how well usual and the shorter treatments work, the study doctors will look at how well each treatment works to prevent cancer from returning.
The study doctors also want to learn if the shorter chemo-immunotherapy improves quality of life for patients. They will be looking to see if it causes fewer side effects than the usual treatment.
All chemotherapy and immunotherapy drugs used in this study are commonly used to treat triple negative breast cancer.
Click Here for more information
Principle Investigator: Priya Gor, MD
Contacts for Participation in Clinical Trials:
Virtua Samson Cancer Center
Theresa Carducci, MSN, RN, BA, CCRP
Lead Clinical Research Nurse
(856) 206-4721
tcarducc@virtua.org
Kristina Montagno, BSN-RN, CCRP
Clinical Research Nurse
(856) 206-4728
kmontag1@virtua.org
Virtua Voorhees
Maria Jenkins, CCRP
Clinical Research Coordinator
(856) 247-7396
mdjenkins@virtua.org
Lori Lodge, MSN, RN
Clinical Research Nurse
(856) 247-7395
llodge1@virtua.org